Spiros P Hiotis, MD, PhD Email Spiros Hiotis
- ASSOCIATE PROFESSOR | Surgery
- ASSISTANT PROFESSOR | Oncological Sciences
- Surgical Oncology
- Chinese (Cantonese)
- Chinese (Mandarin)
- Hospital Affiliations
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
- Mount Sinai Queens
- Mount Sinai Morningside and Mount Sinai West
Dr Hiotis is a Surgical Oncologist at the Mount Sinai School of Medicine. He received his MD degree from the University of Maryland, and also holds a PhD in Immunology. Dr Hiotis trained in General Surgery at the University of South Florida in Tampa, and in Surgical Oncology at the Memorial Sloan-Kettering Cancer Center in New York. He has a strong interest in cancers of the liver and gastrointestinal tract. In addition to clinical practice in surgical oncology, Dr Hiotis is currently actively engaged in both clinical and laboratory research.
He is currently the principal investigator of an independently funded scientific research project, which focuses on the interaction between hepatic fibrosis and hepatocellular carcinoma in patients with hepatitis B. This project involves both a retrospective and prospective component. The prospective arm includes a tumor banking protocol, from which over 100 human tumor and non-neoplastic liver parenchymal specimens have already been collected and cryopreserved. This is a highly unique tumor bank, and only includes hepatocellular cancers from patients with hepatitis B. A broad spectrum of tumors have already been collected from patients with varying degrees of underlying hepatic fibrosis, which is a unique characteristic seen in patients with hepatitis B associated hepatocellular carcinoma. Dr Hiotis’ hepatitis B-hepatocellular carcinoma research project is designed to evaluate differences in hepatocellular carcinoma that arise in patients with underlying cirrhosis, vs. those cancers that arise instead in livers with minimal or moderate fibrosis. His additional research activities also include participation in clinical trials for treatment of liver and gastrointestinal cancers, and basic science research focusing on cancer immunotherapy in a mouse model for hepatocellular carcinoma.
American Board of Surgery
- Abdominal Surgery
- Colorectal Cancer
- Colorectal Surgery
- Esophageal Cancer
- Gallbladder Cancer
- Liver Cancer
- Pancreatic Cancer
- Pelvic Surgery
- Soft Tissue Sarcoma
- Stomach Cancer
MD, University of Maryland
PhD, University of South Florida
Residency, General Surgery
University of South Florida
Fellowship, Surgical Oncology
Memorial Sloan-Kettering Cancer Center
English, Spanish, Greek, Chinese (Cantonese), Chinese (Mandarin)
Dr. Hiotis is currently the Vice Chairman for Surgical Research at Mount Sinai. In this role, Dr. Hiotis administrates the coordinated clinical and basic science research efforts of a large department, including ten divisions and multiple full-time faculty members. He supervises the department’s research fellows, coordinators, and assistants.
In addition to his administrative responsibilities in research, Dr. Hiotis also maintains a research endeavor of his own, oversees a basic science laboratory, and is the principal investigator of independently-funded scientific research. He is also actively engaged in several clinical trials.
His recent open protocols include:
- Hepatocellular carcinoma in non-cirrhotic hepatitis B patient; a prospective analysis of a fibrosis-independent pathway to cancer based on hepatitis B viral DNA levels.
- Treatment of advanced metastatic hepatocellular carcinoma with autologous dendritic cell vaccination
- Cell based immunotherapy of a model for hepatocellular carcinoma
- Risk factors for peritoneal disease and recurrence in gastric cancer
- Factors associated with improved survival in patients with gall bladder cancer
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Hiotis during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Saronic Biotechnology
Service on Board of Directors: Service in a fiduciary capacity, such as an officer or director, for the following companies:
- Saronic Biotechnology
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.